JOP20230113A1 - مشتقات ثلاثية الكربوكساميد كمثبطات prmt5 - Google Patents

مشتقات ثلاثية الكربوكساميد كمثبطات prmt5

Info

Publication number
JOP20230113A1
JOP20230113A1 JOJO/P/2023/0113A JOP20230113A JOP20230113A1 JO P20230113 A1 JOP20230113 A1 JO P20230113A1 JO P20230113 A JOP20230113 A JO P20230113A JO P20230113 A1 JOP20230113 A1 JO P20230113A1
Authority
JO
Jordan
Prior art keywords
tricarboxylamide
derivatives
compounds
prmt5 inhibitors
disorders
Prior art date
Application number
JOJO/P/2023/0113A
Other languages
Arabic (ar)
English (en)
Inventor
Albert Amegadzie
Diane Jennifer Beylkin
Rene Rahimoff
Todd J Kohn
Kexue Li
Qingyian Liu
Primali Vasundera Navaratne
Hui-Ling Wang
John R Butler
Matthew Paul Bourbeau
Shon Booker
Liping H Pettus
Nuria A Tamayo
Sanne Omholt Schroder Glad
Mikkel Vestergaard
Brian Alan Lanman
Patricia Lopez
Francesco Manoni
Nicholas Anthony Weires
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of JOP20230113A1 publication Critical patent/JOP20230113A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
JOJO/P/2023/0113A 2020-11-24 2023-05-23 مشتقات ثلاثية الكربوكساميد كمثبطات prmt5 JOP20230113A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063117937P 2020-11-24 2020-11-24
PCT/US2021/060332 WO2022115377A1 (en) 2020-11-24 2021-11-22 Tricyclic carboxamide derivatives as prmt5 inhibitors

Publications (1)

Publication Number Publication Date
JOP20230113A1 true JOP20230113A1 (ar) 2023-05-23

Family

ID=78957958

Family Applications (1)

Application Number Title Priority Date Filing Date
JOJO/P/2023/0113A JOP20230113A1 (ar) 2020-11-24 2023-05-23 مشتقات ثلاثية الكربوكساميد كمثبطات prmt5

Country Status (17)

Country Link
US (1) US20240101570A1 (cg-RX-API-DMAC7.html)
EP (1) EP4251624B1 (cg-RX-API-DMAC7.html)
JP (1) JP2023550466A (cg-RX-API-DMAC7.html)
KR (1) KR20230113339A (cg-RX-API-DMAC7.html)
CN (1) CN116783191A (cg-RX-API-DMAC7.html)
AU (1) AU2021386149A1 (cg-RX-API-DMAC7.html)
CA (1) CA3202141A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023001461A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023007504A2 (cg-RX-API-DMAC7.html)
CR (1) CR20230286A (cg-RX-API-DMAC7.html)
ES (1) ES3058979T3 (cg-RX-API-DMAC7.html)
IL (1) IL302820B2 (cg-RX-API-DMAC7.html)
JO (1) JOP20230113A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023006145A (cg-RX-API-DMAC7.html)
PE (1) PE20231312A1 (cg-RX-API-DMAC7.html)
SA (1) SA523440916B1 (cg-RX-API-DMAC7.html)
WO (1) WO2022115377A1 (cg-RX-API-DMAC7.html)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11077101B1 (en) 2018-07-18 2021-08-03 Tango Therapeutics, Inc. Compounds and methods of use
US12403137B2 (en) 2019-10-28 2025-09-02 Tango Therapeutics, Inc. Compounds and methods of use
CN116568677B (zh) 2020-07-31 2026-07-28 探戈医药股份有限公司 可用于治疗mtap缺乏和/或mta累积癌症的哌啶-1-基-n-吡啶-3-基-2-氧代乙酰胺衍生物
LT4263545T (lt) * 2020-12-16 2026-07-27 Amgen Inc. Prmt5 inhibitoriai
KR20240054299A (ko) * 2021-08-30 2024-04-25 암젠 인크 나프티리딘 유도체 및 이의 중간체의 합성 방법
CN116462677A (zh) * 2022-01-20 2023-07-21 上海和誉生物医药科技有限公司 一种多稠环prmt5抑制剂及其制备方法和应用
CN116462676A (zh) * 2022-01-20 2023-07-21 上海和誉生物医药科技有限公司 一种多稠环prmt5抑制剂及其制备方法和应用
US12552760B2 (en) * 2022-04-22 2026-02-17 The Board Of Trustees Of The University Of Illinois Compounds for increasing the nicotinamide adenine dinucleotide in a subject and methods of use thereof
WO2023246873A1 (zh) * 2022-06-23 2023-12-28 南京明德新药研发有限公司 氨基取代的杂芳基衍生物及其应用
US20250376473A1 (en) * 2022-07-01 2025-12-11 Cytosinlab Therapeutics Co., Ltd. Prmts inhibitor and use thereof
CN117362304A (zh) * 2022-07-07 2024-01-09 深圳微芯生物科技股份有限公司 一种甲酰胺取代的杂三环类衍生物、其制备方法及其应用
WO2024012308A1 (zh) * 2022-07-15 2024-01-18 上海和誉生物医药科技有限公司 一种prmt5抑制剂,其制备方法和在药学上的应用
CA3257212A1 (en) * 2022-08-03 2025-03-19 Abbisko Therapeutics Co., Ltd. Fused three-cycle PRMT5 inhibitor containing nitrogen, its preparation process and its pharmaceutical use
EP4567038A4 (en) * 2022-08-09 2025-12-10 Shanghai Apeiron Therapeutics Company Ltd NEW PRMT5 INHIBITOR AND ITS USE
WO2024038004A1 (en) 2022-08-15 2024-02-22 Astrazeneca Ab Mta-cooperative prmt5 inhibitors for use in the treatment of cancer
CN121405702A (zh) * 2022-09-26 2026-01-27 上海湃隆生物科技有限公司 新型prmt5抑制剂及其应用
EP4638436A1 (en) * 2022-12-22 2025-10-29 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
CN120418246A (zh) * 2022-12-23 2025-08-01 成都微芯药业有限公司 一类含炔基取代的杂环酰胺衍生物、其制备方法及其应用
JP2026504889A (ja) * 2023-01-18 2026-02-10 アンテンジーン・ディスカバリー・リミテッド Prmt5阻害化合物およびその使用
WO2024170488A1 (en) 2023-02-13 2024-08-22 Astrazeneca Ab Prmt5 inhibitor for use in cancer therapy
CN120957998A (zh) * 2023-03-30 2025-11-14 百济神州(苏州)生物科技有限公司 作为MTA-协同PRMT5抑制剂的5-氨基-6,8-二氢-1H-呋喃并[3,4-d]吡咯并[3,2-b]吡啶-2-甲酰胺衍生物
PE20260121A1 (es) 2023-04-21 2026-01-16 Gilead Sciences Inc Inhibidores de prmt5 y usos de los mismos
WO2024234821A1 (zh) * 2023-05-17 2024-11-21 四川科伦博泰生物医药股份有限公司 三并环酰胺化合物、包含其的药物组合物及其制备方法和用途
WO2024240894A1 (en) * 2023-05-24 2024-11-28 Ryvu Therapeutics S.A. Prmt5 inhibitors
WO2024245412A1 (en) * 2023-06-02 2024-12-05 Insilico Medicine Ip Limited Prmt5 inhibitors and uses thereof
CN121127465A (zh) 2023-07-14 2025-12-12 江苏亚虹医药科技股份有限公司 蛋白质精氨酸酶甲基转移酶-5抑制剂及其医药用途
CN120865197A (zh) * 2023-08-02 2025-10-31 成都微芯药业有限公司 杂环炔基取代的酰胺衍生物、其制备方法及其应用
WO2025031468A1 (zh) 2023-08-09 2025-02-13 江苏恒瑞医药股份有限公司 杂芳基化合物、其制备方法及其在医药上的应用
CN121127472A (zh) 2023-08-18 2025-12-12 江苏亚虹医药科技股份有限公司 蛋白质精氨酸酶甲基转移酶-5抑制剂及其医药用途
US11858935B1 (en) 2023-09-06 2024-01-02 King Faisal University Pyrrolo[2,3-c][1,7]naphthyridine-2-carboxylic acid compounds as CK2 inhibitors
US11891394B1 (en) 2023-09-06 2024-02-06 King Faisal University Pyrrolo[2,3-c][1,6]naphthyridine-8-carboxylic acid compounds as CK2 inhibitors
WO2025113705A1 (zh) * 2023-12-01 2025-06-05 上海翰森生物医药科技有限公司 N-取代酰胺类衍生物抑制剂、其制备方法和应用
WO2025119326A1 (zh) 2023-12-07 2025-06-12 上海湃隆生物科技有限公司 新型prmt5抑制剂及其应用
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025166260A1 (en) * 2024-02-02 2025-08-07 Ideaya Biosciences, Inc. Amide substituted tricyclic guanidino compounds as prmt5 inhibitors
WO2025166257A1 (en) * 2024-02-02 2025-08-07 Ideaya Biosciences, Inc. Amide substituted triheterocyclic guanidino compounds as prmt5 inhibitors
WO2025180517A1 (zh) * 2024-03-01 2025-09-04 武汉人福创新药物研发中心有限公司 含sf5类喹啉衍生物及其作为p2x7拮抗剂的用途
WO2025218671A1 (en) * 2024-04-16 2025-10-23 Shanghai Apeiron Therapeutics Company Limited Novel prmt5 proteolysis targeting chimeric molecules and associated methods of use
US20260130893A1 (en) 2024-10-21 2026-05-14 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
CN119552151B (zh) * 2025-01-24 2025-05-02 赛岚(杭州)生物医药科技有限公司 Prmt5抑制剂及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201604022D0 (en) * 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
EP4063358B1 (en) * 2016-12-22 2024-05-22 Global Blood Therapeutics, Inc. Histone methyltransferase inhibitors
RS65576B1 (sr) * 2017-11-24 2024-06-28 Jubilant Episcribe Llc Heterociklična jedinjenja kao inhibitori prmt5
WO2019209896A1 (en) * 2018-04-25 2019-10-31 Innate Tumor Immunity, Inc. Nlrp3 modulators

Also Published As

Publication number Publication date
ES3058979T3 (en) 2026-03-16
JP2023550466A (ja) 2023-12-01
PE20231312A1 (es) 2023-08-24
CR20230286A (es) 2023-08-24
EP4251624B1 (en) 2025-10-29
IL302820B2 (en) 2026-07-01
IL302820B1 (en) 2026-03-01
AU2021386149A9 (en) 2024-08-08
EP4251624A1 (en) 2023-10-04
SA523440916B1 (ar) 2025-05-07
AU2021386149A1 (en) 2023-06-22
CL2023001461A1 (es) 2023-12-01
CN116783191A (zh) 2023-09-19
US20240101570A1 (en) 2024-03-28
CO2023007504A2 (es) 2023-09-08
WO2022115377A1 (en) 2022-06-02
CA3202141A1 (en) 2022-06-02
IL302820A (en) 2023-07-01
MX2023006145A (es) 2023-06-06
KR20230113339A (ko) 2023-07-28

Similar Documents

Publication Publication Date Title
JOP20230138A1 (ar) مثبطات prmt5
SA523440916B1 (ar) Prmt5 مشتقات كربوكساميد ثلاثية الحلقة كمثبطات
MX2023009222A (es) Inhibidores tricíclicos-amido-bicíclicos de prmt5.
MX2022010011A (es) Inhibidores de prmt5 novedosos.
JOP20220271A1 (ar) مركبات دايازينو بيريميدين كمثبطات لـ her2
ZA202006137B (en) Substituted imidazolidin-2-one derivatives as prmt5 inhibitors
JOP20240165A1 (ar) مشتقات بيبريدينيل سبيرو سيكليك كمثبطات عامل مكمل b واستخداماتها
EA201070167A1 (ru) Замещенные производные индазола, активные как ингибиторы киназы
BR112015028501B8 (pt) Compostos derivados de bipirazol, seus sais, composição compreendendo o composto ou o sal, método de inibição in vitro de uma atividade de jak1, e processo de preparação de sal de ácido fosfórico
JOP20240235A1 (ar) مركبات أريل غير متجانسة لمعالجة الألم
EA200870373A1 (ru) Пиридил- и пиримидинилзамещённые производные пиррола, тиофена и фурана в качестве ингибиторов киназ
PH12022551523A1 (en) Cyclic compounds and methods of using same
EA200700902A1 (ru) 3-ариламинопиридиновые производные
GEP20146146B (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
ATE487720T1 (de) 5,6,7,8-tetrahydropteridin-derivate als hsp90- hemmer
MX2022013890A (es) Sintesis y derivados de acido boronico, formas polimorficas y usos terapeuticos de los mismos.
ZA202002762B (en) Benzimidazole derivatives and their uses
JOP20220281A1 (ar) مركبات وتركيبات لتثبيط نشاط hif2 ألفا وطرق لاستخدامها
MX2023005039A (es) Derivados de 2-hidroxicicloalcan-1-carbamoilo que inhiben la galectina-3.
MX2019012827A (es) Derivados de tetrahidronaftilo urea novedosos.
EA201991916A1 (ru) 1,4,6-ТРИЗАМЕЩЕННЫЕ-2-АЛКИЛ-1H-БЕНЗО[d]ИМИДАЗОЛЬНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ДИГИДРООРОТАТНЫХ ОКСИГЕНАЗНЫХ ИНГИБИТОРОВ
MX2025011346A (es) Compuestos de quinolinona amida y usos de los mismos
EP4635494A3 (en) AMIDO HETERO-ROMATIC COMPOUNDS
JOP20230275A1 (ar) معدلات trex1
MX2023014784A (es) Preparacion de derivados de compuestos 1,2-diaminoheterociclicos sustituidos y su uso como agentes farmaceuticos.